Bristol Myers Squibb (NYSE: BMY), or BMS for short, is starting the week off on a sour note. Specifically, the drugmaker’s shares fell by as much as 4% in early action Monday. BMS’ stock has rebounded modestly as today’s session has progressed, but the pharmaceutical company‘s shares were still in the red by 2.16% as of 10:28 a.m. ET Monday.
German drugmaker Bayer (OTC: BAYR.Y) announced early this morning that it is halting a late-stage trial for the blood thinner asundexian after the drug showed a lack of efficacy against a control arm, according to an independent data monitoring committee. Asundexian belongs to the same class of therapeutics (factor XIa inhibitors) as BMS’ and Johnson & Johnson‘s experimental cardiovascular drug milvexian.
Thus, investors appear to be concerned that asundexian’s underwhelming phase 3 results may be a harbinger of things to come for milvexian. Milvexian is presently in a trio of phase 3 studies for various forms of cardiovascular disease. Top-line readouts from these trials are on track for late 2026 and early 2027, according to clinicaltrials.gov.
Milvexian has been billed as a potential $5 billion-a-year drug by both BMS’ management and some analysts covering its stock. So if the drug fails to reach the market due to a lack of efficacy, the drugmaker will lose one of its most promising future growth drivers.
The bottom line is that BMS sports one of the deeper, more robust pipelines in the industry. So if you’re inclined to bargain hunt, this big pharma stock may be worth adding to your portfolio today.
10 stocks we like better than Bristol Myers Squibb
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Bristol Myers Squibb wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2023
George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
